La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Shanghai Haohai Biological Technology Croissance future
Future contrôle des critères 3/6
Shanghai Haohai Biological Technology devrait augmenter ses bénéfices et ses revenus de 18.2% et de 15.2% par an respectivement, tandis que le BPA devrait croître de croître de 33.4% par an.
Informations clés
18.2%
Taux de croissance des bénéfices
33.4%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.4% |
| Taux de croissance des recettes | 15.2% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 06 Jun 2024 |
Mises à jour récentes de la croissance future
Recent updates
We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease
Jul 25
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?
Feb 23What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?
Feb 05
Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 3,522 | 599 | N/A | N/A | 1 |
| 12/31/2024 | 3,097 | 519 | N/A | N/A | 1 |
| 3/31/2024 | 2,689 | 432 | 239 | 630 | N/A |
| 12/31/2023 | 2,654 | 416 | 367 | 634 | N/A |
| 9/30/2023 | 2,503 | 346 | 99 | 442 | N/A |
| 6/30/2023 | 2,453 | 315 | 92 | 401 | N/A |
| 3/31/2023 | 2,263 | 226 | -35 | 254 | N/A |
| 12/31/2022 | 2,130 | 180 | -86 | 231 | N/A |
| 9/30/2022 | 2,063 | 203 | 52 | 343 | N/A |
| 6/30/2022 | 1,861 | 192 | 57 | 336 | N/A |
| 3/31/2022 | 1,805 | 272 | 64 | 339 | N/A |
| 12/31/2021 | 1,750 | 352 | 70 | 342 | N/A |
| 9/30/2021 | 1,702 | 428 | 115 | 333 | N/A |
| 6/30/2021 | 1,674 | 434 | 120 | 342 | N/A |
| 3/31/2021 | 1,594 | 370 | N/A | N/A | N/A |
| 12/31/2020 | 1,324 | 230 | 66 | 262 | N/A |
| 9/30/2020 | 1,343 | 232 | -20 | 258 | N/A |
| 6/30/2020 | 1,306 | 216 | 6 | 258 | N/A |
| 3/31/2020 | 1,437 | 279 | N/A | N/A | N/A |
| 12/31/2019 | 1,595 | 371 | -50 | 349 | N/A |
| 9/30/2019 | 1,537 | 353 | -8 | 286 | N/A |
| 6/30/2019 | 1,570 | 386 | -7 | 302 | N/A |
| 3/31/2019 | 1,478 | 375 | N/A | N/A | N/A |
| 12/31/2018 | 1,546 | 415 | 239 | 391 | N/A |
| 9/30/2018 | 1,523 | 411 | 235 | 398 | N/A |
| 6/30/2018 | 1,501 | 408 | 231 | 404 | N/A |
| 3/31/2018 | 1,423 | 390 | 220 | 374 | N/A |
| 12/31/2017 | 1,345 | 372 | N/A | 343 | N/A |
| 9/30/2017 | 1,214 | 351 | N/A | 330 | N/A |
| 6/30/2017 | 1,083 | 329 | N/A | 317 | N/A |
| 3/31/2017 | 967 | 317 | N/A | 286 | N/A |
| 12/31/2016 | 851 | 305 | N/A | 254 | N/A |
| 9/30/2016 | 787 | 295 | N/A | 245 | N/A |
| 6/30/2016 | 724 | 284 | N/A | 235 | N/A |
| 3/31/2016 | 694 | 279 | N/A | 252 | N/A |
| 12/31/2015 | 664 | 273 | N/A | 269 | N/A |
| 9/30/2015 | 630 | 258 | N/A | 244 | N/A |
| 6/30/2015 | 597 | 243 | N/A | 219 | N/A |
| 3/31/2015 | 556 | 213 | N/A | 181 | N/A |
| 12/31/2014 | 516 | 184 | N/A | 142 | N/A |
| 9/30/2014 | 482 | 169 | N/A | 135 | N/A |
| 6/30/2014 | 449 | 154 | N/A | 128 | N/A |
| 3/31/2014 | 425 | 148 | N/A | 137 | N/A |
| 12/31/2013 | 401 | 142 | N/A | 147 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 6826 ( 18.2% par an) est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Les bénéfices de 6826 ( 18.2% par an) devraient croître plus rapidement que le marché Hong Kong ( 11% par an).
Croissance élevée des bénéfices: Les bénéfices de 6826 devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 6826 ( 15.2% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 6826 ( 15.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 6826 devrait être élevé dans 3 ans